Literature DB >> 25497326

APOE and mild cognitive impairment: the Framingham Heart Study.

Angela L Jefferson1, Alexa S Beiser2, Sudha Seshadri3, Philip A Wolf3, Rhoda Au3.   

Abstract

BACKGROUND: The risk apolipoprotein E-4 (APOE4) poses for mild cognitive impairment (MCI) may vary based on the neuropsychological definition of MCI.
SETTING: A community-based cohort study.
METHODS: Using two psychometric neuropsychological impairment definitions, we examined APOE4 and prevalent MCI among older adults or pre-MCI among middle-aged adults. Neuropsychological, clinical and genetic data were collected on 2,239 Framingham Offspring Cohort participants free from clinical stroke or dementia (62±9 years; 54% women). Prevalent amnestic MCI was defined from neuropsychological performances≥1.5 SD below the mean based on (i) age and education or (ii) age and Wide Range Achievement Test-3 Reading (WRAT-3 Reading) performance adjustment.
RESULTS: In the entire sample, multivariable-adjusted logistic regressions found that APOE4 was associated with amnestic MCI when using the age and WRAT Reading definition (odds ratio [OR]=1.7, P=0.002) but not the age and education definition (OR=1.0, P=0.90). Results were modified by age, such that APOE4 was associated with amnestic MCI in participants≥65 years using both the age and WRAT Reading definition (OR=2.4, P<0.001) and the age and education definition (OR=1.7, P=0.04).
CONCLUSION: APOE4 risk for prevalent amnestic MCI varies depending on the definition of objective neuropsychological impairment for MCI. Our findings support existing literature emphasising the need to refine MCI neuropsychological profiling methods.
© The Author 2014. Published by Oxford University Press on behalf of the British Geriatrics Society. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  APOE; Alzheimer's disease; genetic risk; mild cognitive impairment; older people; risk factors

Mesh:

Substances:

Year:  2014        PMID: 25497326      PMCID: PMC4400527          DOI: 10.1093/ageing/afu183

Source DB:  PubMed          Journal:  Age Ageing        ISSN: 0002-0729            Impact factor:   10.668


  25 in total

1.  Probability of stroke: a risk profile from the Framingham Study.

Authors:  P A Wolf; R B D'Agostino; A J Belanger; W B Kannel
Journal:  Stroke       Date:  1991-03       Impact factor: 7.914

2.  Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI.

Authors:  J E Hixson; D T Vernier
Journal:  J Lipid Res       Date:  1990-03       Impact factor: 5.922

3.  Cerebrovascular disease, the apolipoprotein e4 allele, and cognitive decline in a community-based study of elderly men.

Authors:  S Kalmijn; E J Feskens; L J Launer; D Kromhout
Journal:  Stroke       Date:  1996-12       Impact factor: 7.914

4.  Midlife smoking, apolipoprotein E and risk of dementia and Alzheimer's disease: a population-based cardiovascular risk factors, aging and dementia study.

Authors:  M Rusanen; S Rovio; T Ngandu; A Nissinen; J Tuomilehto; H Soininen; M Kivipelto
Journal:  Dement Geriatr Cogn Disord       Date:  2010-09-20       Impact factor: 2.959

5.  Increased expression of neuronal apolipoprotein E in human brain with cerebral infarction.

Authors:  Kazuko Aoki; Toshiki Uchihara; Nobuo Sanjo; Ayako Nakamura; Kenji Ikeda; Kuniaki Tsuchiya; Yoshihiro Wakayama
Journal:  Stroke       Date:  2003-03-20       Impact factor: 7.914

6.  Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade.

Authors:  Clifford R Jack; David S Knopman; William J Jagust; Leslie M Shaw; Paul S Aisen; Michael W Weiner; Ronald C Petersen; John Q Trojanowski
Journal:  Lancet Neurol       Date:  2010-01       Impact factor: 44.182

7.  Defining MCI in the Framingham Heart Study Offspring: education versus WRAT-based norms.

Authors:  Richard E Ahl; Alexa Beiser; Sudha Seshadri; Sanford Auerbach; Philip A Wolf; Rhoda Au
Journal:  Alzheimer Dis Assoc Disord       Date:  2013 Oct-Dec       Impact factor: 2.703

8.  Apolipoprotein E in sporadic Alzheimer's disease: allelic variation and receptor interactions.

Authors:  G W Rebeck; J S Reiter; D K Strickland; B T Hyman
Journal:  Neuron       Date:  1993-10       Impact factor: 17.173

9.  New norms for a new generation: cognitive performance in the framingham offspring cohort.

Authors:  Rhoda Au; Sudha Seshadri; Philip A Wolf; Merrill Elias; Penelope Elias; Lisa Sullivan; Alexa Beiser; Ralph B D'Agostino
Journal:  Exp Aging Res       Date:  2004 Oct-Dec       Impact factor: 1.645

10.  The neuropathology of probable Alzheimer disease and mild cognitive impairment.

Authors:  Julie A Schneider; Zoe Arvanitakis; Sue E Leurgans; David A Bennett
Journal:  Ann Neurol       Date:  2009-08       Impact factor: 10.422

View more
  10 in total

1.  Analysis of pleiotropic genetic effects on cognitive impairment, systemic inflammation, and plasma lipids in the Health and Retirement Study.

Authors:  Michael W Lutz; Ramon Casanova; Santiago Saldana; Maragatha Kuchibhatla; Brenda L Plassman; Kathleen M Hayden
Journal:  Neurobiol Aging       Date:  2019-03-06       Impact factor: 4.673

2.  Impact of Apolipoprotein E gene polymorphism during normal and pathological conditions of the brain across the lifespan.

Authors:  Diego Iacono; Gloria C Feltis
Journal:  Aging (Albany NY)       Date:  2019-01-24       Impact factor: 5.682

3.  M1 muscarinic receptor is a key target of neuroprotection, neuroregeneration and memory recovery by i-Extract from Withania somnifera.

Authors:  Arpita Konar; Richa Gupta; Rajendra K Shukla; Bryan Maloney; Vinay K Khanna; Renu Wadhwa; Debomoy K Lahiri; Mahendra K Thakur
Journal:  Sci Rep       Date:  2019-09-30       Impact factor: 4.379

4.  Risk factors for predicting progression from normal cognition to mild cognitive impairment: protocol for a systematic review and meta-analysis of cohort studies.

Authors:  Jie Wang; Lina Wang; Xianglian Zhou; Xiaohong Wen; Xueting Zhen
Journal:  BMJ Open       Date:  2019-06-11       Impact factor: 2.692

5.  Genetic Effects of NDUFAF6 rs6982393 and APOE on Alzheimer's Disease in Chinese Rural Elderly: A Cross-Sectional Population-Based Study.

Authors:  Yingzhe Cheng; Yuanjing Li; Xiaoyan Liang; Pin Wang; Wenxin Fa; Cuicui Liu; Yongxiang Wang; Keke Liu; Nan Wang; Yifeng Du
Journal:  Clin Interv Aging       Date:  2022-02-24       Impact factor: 4.458

Review 6.  Type 2 Diabetes Mellitus as a Risk Factor for Alzheimer's Disease: Review and Meta-Analysis.

Authors:  Athanasia Athanasaki; Konstantinos Melanis; Ioanna Tsantzali; Maria Ioanna Stefanou; Sofia Ntymenou; Sotirios G Paraskevas; Theodosis Kalamatianos; Eleni Boutati; Vaia Lambadiari; Konstantinos I Voumvourakis; George Stranjalis; Sotirios Giannopoulos; Georgios Tsivgoulis; George P Paraskevas
Journal:  Biomedicines       Date:  2022-03-27

7.  Human microRNA (miR-20b-5p) modulates Alzheimer's disease pathways and neuronal function, and a specific polymorphism close to the MIR20B gene influences Alzheimer's biomarkers.

Authors:  Ruizhi Wang; Nipun Chopra; Kwangsik Nho; Bryan Maloney; Alexander G Obukhov; Peter T Nelson; Scott E Counts; Debomoy K Lahiri
Journal:  Mol Psychiatry       Date:  2022-01-27       Impact factor: 13.437

8.  A profile of brain reserve in adults at genetic risk of Alzheimer's disease.

Authors:  Gillian Coughlan; Peter Zhukovsky; Aristotle Voineskos; Cheryl Grady
Journal:  Alzheimers Dement (Amst)       Date:  2021-06-09

9.  Effect of apolipoprotein E ε4 allele on the progression of cognitive decline in the early stage of Alzheimer's disease.

Authors:  Kazushi Suzuki; Akihiro Hirakawa; Ryoko Ihara; Atsushi Iwata; Kenji Ishii; Takeshi Ikeuchi; Chung-Kai Sun; Michael Donohue; Takeshi Iwatsubo
Journal:  Alzheimers Dement (N Y)       Date:  2020-03-20

Review 10.  Mild cognitive impairment: when nutrition helps brain energy rescue-a report from the EuGMS 2020 Congress.

Authors:  Stephen C Cunnane; Cornel C Sieber; Russell H Swerdlow; Alfonso J Cruz-Jentoft
Journal:  Eur Geriatr Med       Date:  2021-07-05       Impact factor: 1.710

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.